The evolving paradigm of prognostic factors in AML: Introduction to the Acute Leukemia Forum 2010

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 453-456

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER INCIDENCE; CYTOGENETICS; EDITORIAL; HUMAN; KARYOTYPE; MINIMAL RESIDUAL DISEASE; MONOSOMY; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 78649973256     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.007     Document Type: Editorial

References (16)

1. M.L. Slovak, K.J. Kopecky, P.A. Cassileth, D.H. Harrington, K.S. Theil, and A. Mohamed Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood 96 2000 4075 4083
2. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, and G. Harrison The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333
3. J.C. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, and D.C. Arthur Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
4. R.F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, and L. Bullinger Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
5. D. Grimwade, and R.K. Hills Independent prognostic factors for AML outcome Hematology Am Soc Hematol Educ Program 2009 385 395
6. B.J. Wouters, B. Lowenberg, C.A. Erpelinck-Verschueren, W.L. van Putten, P.J. Valk, and R. Delwel Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 2009 3088 3091
7. D.A. Breems, W.L. van Putten, G.E. De Greef, S.L. Van Zelderen-Bhola, K.B. Gerssen-Schoorl, and C.H. Mellink Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype J Clin Oncol 26 2008 4791 4797
8. J.F. San Miguel, A. Martinez, A. Macedo, M.B. Vidriales, C. Lopez-Berges, and M. Gonzalez Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood 90 1997 2465 2470
9. D. Cilloni, A. Renneville, F. Hermitte, R.K. Hills, S. Daly, and J.V. Jovanovic Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study J Clin Oncol 27 2009 5195 5201
10. J.O. Moore, S.L. George, R.K. Dodge, P.C. Amrein, B.L. Powell, and J.E. Kolitz Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427
11. H.F. Fernandez, Z. Sun, X. Yao, M.R. Litzow, S.M. Luger, and E.M. Paietta Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
12. T. Buchner, W.E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger, and C. Muller-Tidow Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group J Clin Oncol 27 2009 61 69
13. S. Petersdorf, K. Kopecky, R.K. Stuart, R.A. Larson, T.J. Nevill, and L. Stenke Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia Blood 114 2009 326 (abstr 790)
14. J.M. Rowe, and M.S. Tallman How I treat acute myeloid leukemia Blood 2010 10.1182/blood-2010-05-260117
15. L.D. Cripe, H. Uno, E.M. Paietta, M.R. Litzow, R.P. Ketterling, and J.M. Bennett Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999) Blood 2010 10.1182/blood-2010-04-277269
16. J.M. Rowe Preface: significant advances in the biology and therapy of AML over the past four decades Best Pract Res Clin Haematol 19 2006 259 262